Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 9Stomach Neoplasms 5Triple Negative Breast Neoplasms 3Liver Neoplasms 3Breast Neoplasms 3Small Cell Lung Carcinoma 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Cholangiocarcinoma 2Biliary Tract Neoplasms 2Adrenocortical Carcinoma 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Cancer Limited Stage 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Salivary Gland Neoplasms 1SCLC 1Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Meningioma 1Melanoma 1Malignant Neoplasms of Digestive Organs 1Locally Advanced Thyroid Gland Carcinoma 1Immunotherapy Gastrict Cancer 1HER2-negative Breast Cancer Brain Metastases 1Gestational Trophoblastic Disease 1

Interventions

Bevacizumab 3Paclitaxel 2Lutetium-177 2Lutetium 2ribociclib 1repotrectinib 1regorafenib 1pembrolizumab 1palbociclib 1olaparib 1lutetium Lu 177 dotatate 1copper dotatate CU-64 1camrelizumab 1atezolizumab 1apatinib 1Tretinoin 1Radiation 1Propranolol 1Imatinib Mesylate 1Hyperthermic Intraperitoneal Chemotherapy 1Fulvestrant 1Drug Therapy 1Clinical Trials, Phase II as Topic 1Cisplatin 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Digestive System Neoplasms × apatinib × Clear all
NCT06099821 2023-10-26

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Peking University Cancer Hospital & Institute

Phase 2 Recruiting
39 enrolled
Gastrointestinal

Digestive System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡